Musk's Neuralink to launch feasibility trial with brain implant, robotic arm
FILE PHOTO: A smartphone with a Neuralink logo displayed is placed on a computer motherboard in this illustration taken on May 15, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) -Elon Musk's brain technology startup Neuralink said on Monday it has received approval to launch a new feasibility study using its brain implant and an experimental robotic arm.
Neuralink is conducting its PRIME study, aimed at evaluating the safety of its wireless brain-computer interface and surgical robot. It is assessing the initial effect of the implant in patients with quadriplegia, a form of paralysis, to control external devices with their thoughts.
The company plans to cross-enroll participants in the feasibility study from the ongoing PRIME trial, it said in a post on social media platform X.
The U.S. Food and Drug Administration and Neuralink did not immediately respond to requests for details on the feasibility study.
Last week, the company received approval from regulator Health Canada to launch a trial of its device in Canada. Canadian neurosurgeons in partnership with the startup have regulatory approval to recruit six patients with paralysis in the study.
In the United States, Neuralink has already implanted the device in two patients. It has allowed the first patient to play video games, browse the internet, post on social media and move a cursor on his laptop.
The company has said its device is working well in the second trial patient, who has been using it to play video games and learn how to design 3D objects.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US Attorney General Blanche publicly backs Pirro after Trump criticism over Reflecting Pool
- Trump's envoys meet mediators, Israel strikes Gaza
- Iranian parliament advances bill to curb foreign influence
Create E-mail Alert Related Categories
ReutersRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share